We recently released a list So far, the 11 worst performing stocks in S&P in 500 years. In this article, we will explore the position of Charles River Laboratory International (NYSE:CRL) with other worst-performing stocks this year.
After two years of growth of 53%, marking the best performance of the broad market index since the 1997-98 rally, stocks were taken away in 2025 due to recent tariff uncertainties, resulting in an annual decline of nearly 6%.
Please read also: According to analysts, 11 most promising stocks and 15 Best Dividend Stocks Can Be Used for Long-term Passive Income.
Trends over the past century suggest that sustained high returns are not common. After strong back-to-back performance in the 1920s, the market fell sharply in 1929, marking the beginning of the Great Depression. Then, after recovery in 1935 and 1936, one step back a year later.
A recent report from a leading investment banking firm also pointed out how a bull market historically produced mediocre returns in its third year. Although they are not usually negative. The New York-based company expects positive but depreciating returns in 2025, while also pointing out that the ongoing adoption of artificial intelligence has the potential to lead to productivity booms and stronger market gatherings.
On April 24, the broad market index rose 0.74% on April 24, with the share price of 4.6% this week. The dollar has also risen weekly since March as investors are looking for signs that the ongoing trade war may be easing.
Washington also appears to have eased its position on trade relations with Beijing. Trump said in an interview with Time magazine on April 22 that his administration reached a tariff agreement with China. The U.S. president also hopes to issue announcements on many other trade agreements over the next three to four weeks.
Infracap founder and chief investment officer Jay Hatfield spoke with CNBC, expressed optimism that the most serious uncertainty about tariffs has ended:
“As for the chaos of whether or not we really have negotiations with China, we think we have reached the peak tariff of tantrums, so it may be more positive than negative.”
Chip Rewey, CIO of Rewey Asset Management, said in the case of Reuters:
"This week, you've seen some relief, and maybe the worst-case scenario of Trump's tariff action isn't going to happen. Even though we've recovered from some lows, we haven't returned to the highs. I think somewhere in that range is that we're going to stay for a while."
Having said that, let's start now with the worst performing stocks this year.
A laboratory scientist surrounded by equipment and resources for drug discovery.
In this article, we have browsed the filters to identify the stocks listed on the S&P Index. From there, we selected the 11 worst stocks with year-to-date stock prices since the close of Friday, April 25, 2025.
Why are we interested in stocks that hedge funds to accumulate? The reason is simple: Our research shows that we can beat the market by mimicking the top stocks of the best hedge funds. Our strategy for quarterly newsletters selects 14 small and large stocks every quarter, returning 373.4% since May 2014, beating its benchmark by 218 percentage points (See more details here).
YTD shares fell: -37.22%
Charles River Laboratories International, Inc. (NYSE:CRL) is a pharmaceutical development company that provides essential products and services to help pharmaceutical and biotech companies, academic institutions, and government agencies around the world accelerate their R&D efforts.
It is one of the worst performing stocks this year. The company's stock went bankrupt this month after the FDA announced plans to replace animal testing with more effective methods, such as AI-based models. This decision was a huge blow to Charles River Laboratory International (NYSE:CRL), which relies heavily on preclinical studies based on animals.
Shortly after the announcement, analysts adjusted their Charles River Laboratories International, Inc. (NYSE:CRL) position. This includes Mizuho, reducing its target from $175 to $155, and Barclays raises its target from $160 to $145. CRL's consensus analyst rating is now held, reflecting the growing uncertainty around the company.
Upslope Capital Management pointed out about Charles River Laboratories International, Inc in its Q1 2025. (NYSE:CRL) Investor's letter:
“Charles River Laboratory International Corporation (NYSE: CRL) (CRL, testing, discovery and safety of biological weapons) – for sale due to the rest of the paper, when the FDA announced the gradual emergence of animal testing requirements for certain drugs.
Charles River Laboratory International (NYSE: CRL) plans to announce financial results for the first quarter of fiscal 2025 on May 7. According to forecasts by eight analysts, the company is expected to report earnings per share of $2.06, down from $2.27 in the same period last year.
Overall, CRL Ranked third By far, among the worst performing stocks in the S&P 500 so far, we acknowledge the potential of CRL, but our belief is that AI stocks have greater hope to deliver higher returns and be conducted in a shorter time frame. AI stocks have risen since the beginning of 2025, while popular AI stocks have lost about 25%. If you are looking for AI stocks that are more promising than CRL but have less than 5 times its earnings, check out our report Cheapest AI stocks.
Read the next article: Buy 20 Best AI Stocks Now and According to the billionaire, there are now 30 best stocks
Disclosure: None. This article was originally published in Internal monkey.